Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
Open Access
- 6 March 2018
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 265 (5) , 1115-1122
Abstract
B-cell depleting anti-CD20 monoclonal antibody therapies are being increasingly used as long-term maintenance therapy for neuroinflammatory disease compared to many non-neurological diseases where they are used as remission-inducing agents. While hypogammaglobulinaemia is known to occur in over half of patients treated with medium to long-term B-cell-depleting therapy (in our cohort IgG 38, IgM 56 and IgA 18%), the risk of infections it poses seems to be under-recognised. Here, we report five cases of serious infections associated with hypogammaglobulinaemia occurring in patients receiving rituximab for neuromyelitis optica spectrum disorders. Sixty-four per cent of the whole cohort of patients studied had hypogammaglobulinemia. We discuss the implications of these cases to the wider use of anti-CD20 therapy in neuroinflammatory disease.Keywords
This publication has 26 references indexed in Scilit:
- Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsAnnals of the Rheumatic Diseases, 2013
- B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cellsJournal of Clinical Investigation, 2012
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2011
- Pathogen-specific IgG antibody levels in immunodeficient patients receiving immunoglobulin replacement do not provide additional benefit to therapeutic management over total serum IgGJournal of Allergy and Clinical Immunology, 2011
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximabNeurology, 2011
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosisNeurology, 2010
- Anti‐CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatmentArthritis & Rheumatism, 2008
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisNew England Journal of Medicine, 2008
- Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysisArthritis & Rheumatism, 2007
- Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisArthritis & Rheumatism, 2003